+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cancer Biomarkers Market Research Report by Cancer Type, by Technology, by Application, by End User, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 4858011
  • Report
  • July 2021
  • Region: Global
  • 183 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Cancer Biomarkers Market will Grow to USD 29.94 Billion by 2026, at a CAGR of 11.95%

FEATURED COMPANIES

  • Abbott Laboratories, Inc.
  • Biomerieux
  • Danaher Corporation
  • GE Healthcare
  • Illumina, Inc.
  • Myriad Genetics
  • MORE
The Global Cancer Biomarkers Market size was estimated at USD 15.20 Billion in 2020 and expected to reach USD 16.97 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 11.95% to reach USD 29.94 Billion by 2026.



Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Cancer Biomarkers to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Cancer Type, the Cancer Biomarkers Market was examined across Blood Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Skin Cancer, and Stomach Cancer.
  • Based on Biomolecule Type, the Cancer Biomarkers Market was examined across Epigenetic, Genetic, Metabolic, and Proteomic.
  • Based on Technology, the Cancer Biomarkers Market was examined across Bioinformatics, Cytogenetics, Imaging Technology, Immunoassays, and OMICS Technology.
  • Based on Application, the Cancer Biomarkers Market was examined across Diagnostics, Drug Discovery and Development, Prognostics, and Risk Assessment.
  • Based on End User, the Cancer Biomarkers Market was examined across Academic and Cancer Research Centers, Hospitals, and Speciality Centers.
  • Based on Geography, the Cancer Biomarkers Market was examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas was further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific was further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa was further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. This ongoing research amplifies this research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cancer Biomarkers Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cancer Biomarkers Market, including Abbott Laboratories, Inc., Agilent Technologies, Becton, Dickinson and Company, Bio-Rad Laboratories, Biomerieux, Danaher Corporation, F. Hoffmann-La Roche Ltd, GE Healthcare, Hologic, Illumina, Inc., Merck & Co., Myriad Genetics, Qiagen N.V., Quest Diagnostics, Roche Diagnostics, Sysmex Corporation, and Thermo Fisher Scientific.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cancer Biomarkers Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Biomarkers Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Biomarkers Market?
4. What is the competitive strategic window for opportunities in the Global Cancer Biomarkers Market?
5. What are the technology trends and regulatory frameworks in the Global Cancer Biomarkers Market?
6. What is the market share of the leading vendors in the Global Cancer Biomarkers Market?
7. What modes and strategic moves are considered suitable for entering the Global Cancer Biomarkers Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories, Inc.
  • Biomerieux
  • Danaher Corporation
  • GE Healthcare
  • Illumina, Inc.
  • Myriad Genetics
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Cancer Type Outlook
3.4. Biomolecule Type Outlook
3.5. Technology Outlook
3.6. Application Outlook
3.7. End User Outlook
3.8. Geography Outlook
3.9. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing instances of cancer globally and higher acceptance for treatment in developing economies
5.1.1.2. Paradigm Shift in Healthcare from Disease Diagnosis to Risk Assessment or Early Diagnosis
5.1.1.3. Technology advancement coupled with the research on cancer biomarkers
5.1.1.4. Increasing Use of Cancer Biomarkers in Drug Discovery and Development
5.1.2. Restraints
5.1.2.1. Unfavourable reimbursement policies and regulatory framework
5.1.2.2. Technical issues related to sample collection and storage
5.1.3. Opportunities
5.1.3.1. Growing demand for personalized medicines
5.1.3.2. Trend of the companion diagnostic for the safe and effective use of a corresponding drug or biological product
5.1.4. Challenges
5.1.4.1. High capital investment associated with low benefit ratio
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Cancer Biomarkers Market, by Cancer Type
6.1. Introduction
6.2. Blood Cancer
6.3. Breast Cancer
6.4. Colorectal Cancer
6.5. Lung Cancer
6.6. Ovarian Cancer
6.7. Prostate Cancer
6.8. Skin Cancer
6.9. Stomach Cancer

7. Cancer Biomarkers Market, by Biomolecule Type
7.1. Introduction
7.2. Epigenetic
7.3. Genetic
7.4. Metabolic
7.5. Proteomic

8. Cancer Biomarkers Market, by Technology
8.1. Introduction
8.2. Bioinformatics
8.3. Cytogenetics
8.4. Imaging Technology
8.5. Immunoassays
8.6. OMICS Technology

9. Cancer Biomarkers Market, by Application
9.1. Introduction
9.2. Diagnostics
9.3. Drug Discovery and Development
9.4. Prognostics
9.5. Risk Assessment

10. Cancer Biomarkers Market, by End User
10.1. Introduction
10.2. Academic and Cancer Research Centers
10.3. Hospitals
10.4. Speciality Centers

11. Americas Cancer Biomarkers Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Cancer Biomarkers Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Thailand

13. Europe, Middle East & Africa Cancer Biomarkers Market
13.1. Introduction
13.2. France
13.3. Germany
13.4. Italy
13.5. Netherlands
13.6. Qatar
13.7. Russia
13.8. Saudi Arabia
13.9. South Africa
13.10. Spain
13.11. United Arab Emirates
13.12. United Kingdom

14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion

15. Company Usability Profiles
15.1. Abbott Laboratories, Inc.
15.2. Agilent Technologies
15.3. Becton, Dickinson and Company
15.4. Bio-Rad Laboratories
15.5. Biomerieux
15.6. Danaher Corporation
15.7. F. Hoffmann-La Roche Ltd
15.8. GE Healthcare
15.9. Hologic
15.10. Illumina, Inc.
15.11. Merck & Co.
15.12. Myriad Genetics
15.13. Qiagen N.V.
15.14. Quest Diagnostics
15.15. Roche Diagnostics
15.16. Sysmex Corporation
15.17. Thermo Fisher Scientific

16. Appendix
16.1. Discussion Guide
16.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2020 VS 2026 (USD BILLION)
FIGURE 2. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2020 (USD BILLION)
FIGURE 3. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2020 (USD BILLION)
FIGURE 4. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2020 (USD BILLION)
FIGURE 5. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2020 (USD BILLION)
FIGURE 6. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2020 (USD BILLION)
FIGURE 7. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2020 (USD BILLION)
FIGURE 8. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 9. GLOBAL CANCER BIOMARKERS MARKET: MARKET DYNAMICS
FIGURE 10. GLOBAL CANCER BIOMARKERS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 11. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2020 VS 2026 (%)
FIGURE 12. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2020 VS 2026 (USD BILLION)
FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2026
FIGURE 14. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BLOOD CANCER, 2018-2026 (USD BILLION)
FIGURE 15. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BLOOD CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 16. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BREAST CANCER, 2018-2026 (USD BILLION)
FIGURE 17. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 18. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COLORECTAL CANCER, 2018-2026 (USD BILLION)
FIGURE 19. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COLORECTAL CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 20. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY LUNG CANCER, 2018-2026 (USD BILLION)
FIGURE 21. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY LUNG CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 22. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OVARIAN CANCER, 2018-2026 (USD BILLION)
FIGURE 23. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OVARIAN CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 24. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, 2018-2026 (USD BILLION)
FIGURE 25. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 26. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SKIN CANCER, 2018-2026 (USD BILLION)
FIGURE 27. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SKIN CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 28. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY STOMACH CANCER, 2018-2026 (USD BILLION)
FIGURE 29. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY STOMACH CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 30. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2020 VS 2026 (%)
FIGURE 31. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2020 VS 2026 (USD BILLION)
FIGURE 32. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2026
FIGURE 33. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY EPIGENETIC, 2018-2026 (USD BILLION)
FIGURE 34. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY EPIGENETIC, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 35. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2026 (USD BILLION)
FIGURE 36. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GENETIC, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 37. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY METABOLIC, 2018-2026 (USD BILLION)
FIGURE 38. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY METABOLIC, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 39. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROTEOMIC, 2018-2026 (USD BILLION)
FIGURE 40. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROTEOMIC, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 41. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2020 VS 2026 (%)
FIGURE 42. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2020 VS 2026 (USD BILLION)
FIGURE 43. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2026
FIGURE 44. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOINFORMATICS, 2018-2026 (USD BILLION)
FIGURE 45. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOINFORMATICS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 46. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CYTOGENETICS, 2018-2026 (USD BILLION)
FIGURE 47. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CYTOGENETICS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 48. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2026 (USD BILLION)
FIGURE 49. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGY, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 50. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMMUNOASSAYS, 2018-2026 (USD BILLION)
FIGURE 51. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMMUNOASSAYS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 52. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OMICS TECHNOLOGY, 2018-2026 (USD BILLION)
FIGURE 53. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OMICS TECHNOLOGY, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 54. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2020 VS 2026 (%)
FIGURE 55. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2020 VS 2026 (USD BILLION)
FIGURE 56. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2026
FIGURE 57. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD BILLION)
FIGURE 58. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 59. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, 2018-2026 (USD BILLION)
FIGURE 60. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 61. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROGNOSTICS, 2018-2026 (USD BILLION)
FIGURE 62. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 63. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY RISK ASSESSMENT, 2018-2026 (USD BILLION)
FIGURE 64. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY RISK ASSESSMENT, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 65. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2020 VS 2026 (%)
FIGURE 66. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2020 VS 2026 (USD BILLION)
FIGURE 67. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2026
FIGURE 68. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY ACADEMIC AND CANCER RESEARCH CENTERS, 2018-2026 (USD BILLION)
FIGURE 69. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY ACADEMIC AND CANCER RESEARCH CENTERS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 70. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY HOSPITALS, 2018-2026 (USD BILLION)
FIGURE 71. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY HOSPITALS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 72. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SPECIALITY CENTERS, 2018-2026 (USD BILLION)
FIGURE 73. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SPECIALITY CENTERS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 74. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 75. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 76. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 77. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 78. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 79. CANADA CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 80. MEXICO CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 81. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 82. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 83. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 84. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 85. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 86. CHINA CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 87. INDIA CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 88. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 89. JAPAN CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 90. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 91. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 92. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 93. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 94. THAILAND CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 95. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 96. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 97. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 98. FRANCE CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 99. GERMANY CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 100. ITALY CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 101. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 102. QATAR CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 103. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 104. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 105. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 106. SPAIN CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 107. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 108. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 109. GLOBAL CANCER BIOMARKERS MARKET: FPNV POSITIONING MATRIX
FIGURE 110. GLOBAL CANCER BIOMARKERS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 111. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL CANCER BIOMARKERS MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL CANCER BIOMARKERS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 4. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 5. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BLOOD CANCER, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 6. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 7. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COLORECTAL CANCER, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 8. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY LUNG CANCER, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 9. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OVARIAN CANCER, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 10. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 11. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SKIN CANCER, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 12. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY STOMACH CANCER, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 13. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 14. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY EPIGENETIC, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 15. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GENETIC, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 16. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY METABOLIC, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 17. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROTEOMIC, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 18. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 19. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOINFORMATICS, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 20. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CYTOGENETICS, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 21. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGY, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 22. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMMUNOASSAYS, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 23. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OMICS TECHNOLOGY, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 24. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 25. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 26. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 27. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 28. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY RISK ASSESSMENT, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 29. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 30. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY ACADEMIC AND CANCER RESEARCH CENTERS, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 31. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY HOSPITALS, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 32. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SPECIALITY CENTERS, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 33. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 34. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 35. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 36. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 37. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 38. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 39. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 40. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 41. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 42. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 43. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 44. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 45. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 46. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 47. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 48. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 49. CANADA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 50. CANADA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 51. CANADA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 52. CANADA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 53. CANADA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 54. MEXICO CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 55. MEXICO CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 56. MEXICO CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 57. MEXICO CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 58. MEXICO CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 59. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 60. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 61. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 62. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 63. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 64. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 65. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 66. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 67. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 68. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 69. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 70. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 71. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 72. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 73. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 74. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 75. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 76. CHINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 77. CHINA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 78. CHINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 79. CHINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 80. CHINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 81. INDIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 82. INDIA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 83. INDIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 84. INDIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 85. INDIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 86. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 87. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 88. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 89. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 90. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 91. JAPAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 92. JAPAN CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 93. JAPAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 94. JAPAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 95. JAPAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 96. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 97. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 98. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 99. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 100. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 101. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 102. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 103. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 104. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 105. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 106. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 107. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 108. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 109. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 110. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 111. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 112. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 113. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 114. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 115. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 116. THAILAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 117. THAILAND CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 118. THAILAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 119. THAILAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 120. THAILAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 127. FRANCE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 128. FRANCE CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 129. FRANCE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 130. FRANCE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 131. FRANCE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 132. GERMANY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 133. GERMANY CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 134. GERMANY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 135. GERMANY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 136. GERMANY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 137. ITALY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 138. ITALY CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 139. ITALY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 140. ITALY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 141. ITALY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 142. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 143. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 144. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 145. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 146. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 147. QATAR CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 148. QATAR CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 149. QATAR CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 150. QATAR CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 151. QATAR CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 152. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 153. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 154. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 155. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 156. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 157. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 158. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 159. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 160. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 161. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 162. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 163. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 164. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 165. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 166. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 167. SPAIN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 168. SPAIN CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 169. SPAIN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 170. SPAIN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 171. SPAIN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 172. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 173. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 174. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 175. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 176. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 177. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD BILLION)
TABLE 178. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2026 (USD BILLION)
TABLE 179. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD BILLION)
TABLE 180. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 181. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 182. GLOBAL CANCER BIOMARKERS MARKET: SCORES
TABLE 183. GLOBAL CANCER BIOMARKERS MARKET: BUSINESS STRATEGY
TABLE 184. GLOBAL CANCER BIOMARKERS MARKET: PRODUCT SATISFACTION
TABLE 185. GLOBAL CANCER BIOMARKERS MARKET: RANKING
TABLE 186. GLOBAL CANCER BIOMARKERS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 187. GLOBAL CANCER BIOMARKERS MARKET: MERGER & ACQUISITION
TABLE 188. GLOBAL CANCER BIOMARKERS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 189. GLOBAL CANCER BIOMARKERS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 190. GLOBAL CANCER BIOMARKERS MARKET: INVESTMENT & FUNDING
TABLE 191. GLOBAL CANCER BIOMARKERS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 192. GLOBAL CANCER BIOMARKERS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Abbott Laboratories, Inc.
  • Agilent Technologies
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories
  • Biomerieux
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Hologic
  • Illumina, Inc.
  • Merck & Co.
  • Myriad Genetics
  • Qiagen N.V.
  • Quest Diagnostics
  • Roche Diagnostics
  • Sysmex Corporation
  • Thermo Fisher Scientific
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll